NCT02250508View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2005

Conditions
vonWillebrand's Disease
Interventions
BIOLOGICAL

Optivate® (Human Coagulation Factor VIII)

BIOLOGICAL

Haemate P® (Human Coagulation Factor VIII)

Trial Locations (1)

Unknown

Hematology Dept., Sackler School of Medicine, Tel Aviv University, Tel Aviv

Sponsors
All Listed Sponsors
lead

Bio Products Laboratory

OTHER